Loading…
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of actio...
Saved in:
Published in: | Human psychopharmacology 2008-06, Vol.23 (4), p.275-281 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3 |
container_end_page | 281 |
container_issue | 4 |
container_start_page | 275 |
container_title | Human psychopharmacology |
container_volume | 23 |
creator | Karagianis, Jamie Hoffmann, Vicki Poole Arranz, Belen Treuer, Tamás Maguire, Gerald A. de Haan, Lieuwe Chawla, Bharat |
description | Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/hup.933 |
format | article |
fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_hup_933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_SBPPQW0B_M</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgiptT_AbSmwep5k-bpEcV3QR1ExUvQkibt120y0pSmfPTW-nQk6f3hefHc3gQOiT4lGBMz-YfzWnG2BYaEpxlMcFCbKMhljKNOaV0gPZCeMO4y3C2iwZEMiYTyofodep1Xa8jY4N1LVRet9ZV0bLW7ks31kGknYmaZQuutbruXFmCB1dAiKyLWg-6XXRZDAvwVfdEK7DVvI0qbd0-2il1HeBgc0fo-frq6XIS307HN5fnt3HBUsZikwgAnvM8NyQtkjShEguZizKlRvBEclZoQVPCCce0MKWkkHFCuZG6oIYWbISO-97CL0PwUKrG24X2a0Ww-tlHdfuobp9OHvWy-cgXYP7cZpAOnPRgZWtY_9ejJs-zvi7utQ0tfP5q7d8VF0yk6uV-rB4vZrOHF3yh7tg3KYZ_OQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</title><source>Wiley</source><creator>Karagianis, Jamie ; Hoffmann, Vicki Poole ; Arranz, Belen ; Treuer, Tamás ; Maguire, Gerald A. ; de Haan, Lieuwe ; Chawla, Bharat</creator><creatorcontrib>Karagianis, Jamie ; Hoffmann, Vicki Poole ; Arranz, Belen ; Treuer, Tamás ; Maguire, Gerald A. ; de Haan, Lieuwe ; Chawla, Bharat</creatorcontrib><description>Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0885-6222</identifier><identifier>EISSN: 1099-1077</identifier><identifier>DOI: 10.1002/hup.933</identifier><identifier>PMID: 18338426</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Administration, Oral ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; atypical antipsychotic ; Benzodiazepines - administration & dosage ; Benzodiazepines - adverse effects ; Benzodiazepines - therapeutic use ; disintegrating ; dissolving ; Drug Delivery Systems ; Humans ; olanzapine ; Patient Compliance ; Schizophrenia - drug therapy ; Solubility ; Tablets ; weight ; Weight Gain - drug effects</subject><ispartof>Human psychopharmacology, 2008-06, Vol.23 (4), p.275-281</ispartof><rights>Copyright © 2008 John Wiley & Sons, Ltd.</rights><rights>(c) 2008 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</citedby><cites>FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18338426$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karagianis, Jamie</creatorcontrib><creatorcontrib>Hoffmann, Vicki Poole</creatorcontrib><creatorcontrib>Arranz, Belen</creatorcontrib><creatorcontrib>Treuer, Tamás</creatorcontrib><creatorcontrib>Maguire, Gerald A.</creatorcontrib><creatorcontrib>de Haan, Lieuwe</creatorcontrib><creatorcontrib>Chawla, Bharat</creatorcontrib><title>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</title><title>Human psychopharmacology</title><addtitle>Hum. Psychopharmacol. Clin. Exp</addtitle><description>Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.</description><subject>Administration, Oral</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>atypical antipsychotic</subject><subject>Benzodiazepines - administration & dosage</subject><subject>Benzodiazepines - adverse effects</subject><subject>Benzodiazepines - therapeutic use</subject><subject>disintegrating</subject><subject>dissolving</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>olanzapine</subject><subject>Patient Compliance</subject><subject>Schizophrenia - drug therapy</subject><subject>Solubility</subject><subject>Tablets</subject><subject>weight</subject><subject>Weight Gain - drug effects</subject><issn>0885-6222</issn><issn>1099-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp10E9LwzAYBvAgiptT_AbSmwep5k-bpEcV3QR1ExUvQkibt120y0pSmfPTW-nQk6f3hefHc3gQOiT4lGBMz-YfzWnG2BYaEpxlMcFCbKMhljKNOaV0gPZCeMO4y3C2iwZEMiYTyofodep1Xa8jY4N1LVRet9ZV0bLW7ks31kGknYmaZQuutbruXFmCB1dAiKyLWg-6XXRZDAvwVfdEK7DVvI0qbd0-2il1HeBgc0fo-frq6XIS307HN5fnt3HBUsZikwgAnvM8NyQtkjShEguZizKlRvBEclZoQVPCCce0MKWkkHFCuZG6oIYWbISO-97CL0PwUKrG24X2a0Ww-tlHdfuobp9OHvWy-cgXYP7cZpAOnPRgZWtY_9ejJs-zvi7utQ0tfP5q7d8VF0yk6uV-rB4vZrOHF3yh7tg3KYZ_OQ</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Karagianis, Jamie</creator><creator>Hoffmann, Vicki Poole</creator><creator>Arranz, Belen</creator><creator>Treuer, Tamás</creator><creator>Maguire, Gerald A.</creator><creator>de Haan, Lieuwe</creator><creator>Chawla, Bharat</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200806</creationdate><title>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</title><author>Karagianis, Jamie ; Hoffmann, Vicki Poole ; Arranz, Belen ; Treuer, Tamás ; Maguire, Gerald A. ; de Haan, Lieuwe ; Chawla, Bharat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Administration, Oral</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>atypical antipsychotic</topic><topic>Benzodiazepines - administration & dosage</topic><topic>Benzodiazepines - adverse effects</topic><topic>Benzodiazepines - therapeutic use</topic><topic>disintegrating</topic><topic>dissolving</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>olanzapine</topic><topic>Patient Compliance</topic><topic>Schizophrenia - drug therapy</topic><topic>Solubility</topic><topic>Tablets</topic><topic>weight</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karagianis, Jamie</creatorcontrib><creatorcontrib>Hoffmann, Vicki Poole</creatorcontrib><creatorcontrib>Arranz, Belen</creatorcontrib><creatorcontrib>Treuer, Tamás</creatorcontrib><creatorcontrib>Maguire, Gerald A.</creatorcontrib><creatorcontrib>de Haan, Lieuwe</creatorcontrib><creatorcontrib>Chawla, Bharat</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Human psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karagianis, Jamie</au><au>Hoffmann, Vicki Poole</au><au>Arranz, Belen</au><au>Treuer, Tamás</au><au>Maguire, Gerald A.</au><au>de Haan, Lieuwe</au><au>Chawla, Bharat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain</atitle><jtitle>Human psychopharmacology</jtitle><addtitle>Hum. Psychopharmacol. Clin. Exp</addtitle><date>2008-06</date><risdate>2008</risdate><volume>23</volume><issue>4</issue><spage>275</spage><epage>281</epage><pages>275-281</pages><issn>0885-6222</issn><eissn>1099-1077</eissn><abstract>Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine. Copyright © 2008 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>18338426</pmid><doi>10.1002/hup.933</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0885-6222 |
ispartof | Human psychopharmacology, 2008-06, Vol.23 (4), p.275-281 |
issn | 0885-6222 1099-1077 |
language | eng |
recordid | cdi_crossref_primary_10_1002_hup_933 |
source | Wiley |
subjects | Administration, Oral Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use atypical antipsychotic Benzodiazepines - administration & dosage Benzodiazepines - adverse effects Benzodiazepines - therapeutic use disintegrating dissolving Drug Delivery Systems Humans olanzapine Patient Compliance Schizophrenia - drug therapy Solubility Tablets weight Weight Gain - drug effects |
title | Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T02%3A57%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Orally%20disintegrating%20olanzapine%20and%20potential%20differences%20in%20treatment-emergent%20weight%20gain&rft.jtitle=Human%20psychopharmacology&rft.au=Karagianis,%20Jamie&rft.date=2008-06&rft.volume=23&rft.issue=4&rft.spage=275&rft.epage=281&rft.pages=275-281&rft.issn=0885-6222&rft.eissn=1099-1077&rft_id=info:doi/10.1002/hup.933&rft_dat=%3Cistex_cross%3Eark_67375_WNG_SBPPQW0B_M%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3533-d47ee6b6bbd15c45428078b7f52d764863ca725161602cdf82e96126d8ac2d2c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/18338426&rfr_iscdi=true |